Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Exploring T cell therapy for Type 1 Diabetes: mechanism of action of Teplizumab

EF 2022-23

Résumé
Type 1 Diabetes (T1D) is a life-long disease that is most common in children, teens, and young adults. T1D is believed to occur when the body attacks itself by mistake. When this happens, the cells in the pancreas (beta cells) that produce insulin, are destroyed. Although insulin manages T1D, there is no effective prevention or cure for the disease. Therefore, it is important to research a potential therapy to help patients with T1D. Recently, an antibody, known as Teplizumab was successfully approved by the Food and Drug Administration (FDA) for delaying the onset of T1D. Antibodies are proteins that circulate the blood, recognize foreign substances, and neutralize them. Studies have shown that Teplizumab can delay progression of beta cell loss and onset of T1D and can also improve the ability of beta cells to produce and release insulin in some patients. However, it remains to be determined how Teplizumab exerts these effects. Although the majority of beta cells are destroyed in T1D, some can escape. However, these ‘survivor’ beta cells stop working properly. The aim of this project is to determine whether Teplizumab treatment leads to improvement in the function of beta cells by limiting the number of poorly functioning ‘survivor’ beta cells. To do this, we will use a well-studied mouse model of T1D and perform antibody treatments that mimic Teplizumab treatment in T1D patients. Understanding how antibodies like Teplizumab affect beta cells will improve the path to clinical translation by helping us to know which patients may benefit most from this therapy. This work will help to develop a treatment for T1D that could improve the lives of many young people living with or at risk of developing this disease.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486226
Name
Pipella Jasmine
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring T cell therapy for Type 1 Diabetes: mechanism of action of Teplizumab
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoimmunity; Immunotherapy; Pancreatic Beta Cells; Senescence; Teplizumab; Type 1 Diabetes
Abstract
Type 1 Diabetes (T1D) is a life-long disease that is most common in children, teens, and young adults. T1D is believed to occur when the body attacks itself by mistake. When this happens, the cells in the pancreas (beta cells) that produce insulin, are destroyed. Although insulin manages T1D, there is no effective prevention or cure for the disease. Therefore, it is important to research a potential therapy to help patients with T1D. Recently, an antibody, known as Teplizumab was successfully approved by the Food and Drug Administration (FDA) for delaying the onset of T1D. Antibodies are proteins that circulate the blood, recognize foreign substances, and neutralize them. Studies have shown that Teplizumab can delay progression of beta cell loss and onset of T1D and can also improve the ability of beta cells to produce and release insulin in some patients. However, it remains to be determined how Teplizumab exerts these effects. Although the majority of beta cells are destroyed in T1D, some can escape. However, these ‘survivor’ beta cells stop working properly. The aim of this project is to determine whether Teplizumab treatment leads to improvement in the function of beta cells by limiting the number of poorly functioning ‘survivor’ beta cells. To do this, we will use a well-studied mouse model of T1D and perform antibody treatments that mimic Teplizumab treatment in T1D patients. Understanding how antibodies like Teplizumab affect beta cells will improve the path to clinical translation by helping us to know which patients may benefit most from this therapy. This work will help to develop a treatment for T1D that could improve the lives of many young people living with or at risk of developing this disease.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pipella, Jasmine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~
University of Manitoba - $17,500 Grant (2022-23) | Canada Spends